1.845
Sellas Life Sciences Group Inc (SLS) 最新ニュース
What analysts say about SELLAS Life Sciences Group Inc. stockDynamic capital growth - Autocar Professional
What drives SELLAS Life Sciences Group Inc. stock priceFree Stock Index Interpretation - jammulinksnews.com
Is SELLAS Life Sciences Group Inc. a good long term investmentFree Bull & Bear Market Updates - jammulinksnews.com
SELLAS Life Sciences Group Inc. Stock Analysis and ForecastFree Advanced Stock Screener Access - jammulinksnews.com
What makes SELLAS Life Sciences Group Inc. stock attractive to long term investorsMomentum Swing Watchlist - beatles.ru
SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Expected to Rise, Maxim Group Analyst Says - Defense World
Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities - Finansavisen
Sellas Life Sciences shares fall 1.58% premarket after meeting primary endpoints in Phase 2 trial. - AInvest
SELLAS Meets All Primary Endpoints in Phase 2 Trial of - GlobeNewswire
Sellas Targets Tambiciclib To Adverse-Risk Frontline AML Patients After Phase II Success - insights.citeline.com
What makes SELLAS Life Sciences Group Inc. stock price move sharplyReal Time Breakout Tracking - Newser
How SELLAS Life Sciences Group Inc. stock performs during market volatilityHigh Yield Opportunities - Newser
Sellas Flat on Trial Success - Baystreet.ca
Sellas Life Sciences Meets Primary Endpoints in Mid-Stage SLS009 Trial - MarketScreener
SELLAS gains on mid-stage trial win for leukemia drug (SLS) - Seeking Alpha
SELLAS' Phase 2 Study Of SLS009 In Acute Myeloid Leukemia Meets All Primary Goals - Nasdaq
Why SELLAS Life Sciences Group Inc. stock attracts strong analyst attentionSolid Return Trade Selections - Newser
SELLAS Life Sciences Group Reports Positive Phase 2 Trial Results for SLS009 in Relapsed/Refractory Acute Myeloid Leukemia - Nasdaq
SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study - The Manila Times
SELLAS Life Sciences Soars 14.21% on Key Appointment - AInvest
SELLAS Life Sciences Group Inc (SLS) Stock: A Year of Market Movement, Down and Up - investchronicle.com
SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 3.7% – Here’s What Happened - Defense World
SELLAS Life Sciences adds cancer research expert to scientific board By Investing.com - Investing.com Nigeria
SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board - citybiz
SELLAS Life Sciences adds cancer research expert to scientific board - Investing.com
Cancer Research Leader from MD Anderson Strengthens SELLAS Scientific Board Ahead of Key Milestones - Stock Titan
SELLAS Life Sciences Group, Inc.(NasdaqCM: SLS) added to Russell 2500 Growth Index - MarketScreener
大文字化:
|
ボリューム (24 時間):